novo nordisk oral semaglutide brand name The U.S. Food and Drug Administration approved Nordisk's (Wegovy) as the first GLP-1 pill for obesity and cardiovascular risk reduction, with the company targeting an early 2026 launch. Novo Company of the year 2023:

Cytokine 170 , 156338 (2023)

conducted a magnetic resonance imaging (MRI) study and found that long-term chronic hyperglycemia can mediate hippocampal dysfunction, 19 and hyperglycemia inflammatory mediators, rheological factors, and dysregulation of the hypothalamicpituitaryadrenal axis also may exacerbate cognitive decline

The sales page and FAQ say "refund with no questions asked," but the Terms & Conditions reference returns for "damaged" products specifically

Acute pancreatitis occurred in 3 of 1,306 semaglutide participants in STEP 1 (about 0.23 percent)

During clinical trials, people took Wegovy for 68 weeks (15 months)